news

Our latest
Press Releases & Updates

Latest press releases

Ikerian Announces Series B Funding First close of USD 8M Led by Sanoptis with Commercial Agreement to Expand RetinAI Discovery in Europe

Ikerian has secured USD 8M (CHF 6.73M) in the first close of its Series B round, led by Sanoptis, to enhance its AI-driven RetinAI Discovery platform and expand into new therapeutic areas.

RetinAI Partners with MAXO to Advance Clinical Studies in Dry Eye Disease

RetinAI partners with MAXO and TFS HealthScience to support two pivotal dry eye disease studies.

Ikerian (parent company of RetinAI U.S. Inc.) receives EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models

Ikerian (parent company of RetinAI U.S. Inc.) receives EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

Latest updates

124E International Congress de la SFO [MAY'18]

RetinAI had the pleasure to present in the 124e Congrès International de la Société Française d'Ophthalmologie in the session: 'L'impact de l'intelligence artificielle dans la santé visuelle', organised by Optic 2000 in Paris! Wonderful day presenting how AI and machine learning are changing the current paradigm of screening and monitoring of eye diseases.

ARVO 2018 Honolulu - Hawaï [APRIL-MAY'18]

RetinAI is getting ready for the American Research in Vision and Ophthalmology #ARVO2018 in Hawaii! Come to our booth 1039 if you want to learn about how #AI is changing the world of ophthalmic care!

Bilan Magazine TOP 50 Startups in which to invest 2018 [FEBRUARY'18]

RetinAI has been selected as one of the TOP50 Swiss startups in which to invest by the Bilan Magazine. The committee of experts evaluated the progress and projection of hundreds of startups from the Swiss ecosystem and selected the 50 most promising technologies for 2018! Congratulations to the team for this great success.

Read more

Venture Kick Phase III [DECEMBER'17]

Early detection of eye diseases is key for effective treatment to reduce the onset of blindness. However, the patient’s journey to diagnosis is often long and involves many challenges. Venture Kick just awarded RetinAI with 130'000.- CHF to make eye care accessible and affordable to everyone via artificial intelligence.

Read more

Contact us for more informations! We are happy to hear from you!